Yazar "Laktionov, K." seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC(Elsevier Science Inc, 2018) Halmos, B.; Luft, A.; Majem, M.; Hui, R.; Corre, R.; Gumus, M.; Laktionov, K.[Abstract Not Available]Öğe Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407(Oxford Univ Press, 2018) Mazieres, J.; Kowalski, D.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Laktionov, K.[Abstract Not Available]
